




Figure 1. Infections in patients with and without advanced CKD treated with rituximab.

Table S1. Comparison of SVV patients with and without advanced CKD.

Parameter	Average values	Advanced CKD n=9	No advanced CKD n=11	p-value
Age [years]	mean±SD	51±16	45±11	0.308*
Sex:				
Male	n (%)	4 (44%)	6 (55%)	1.000 [#]
Female	n (%)	5 (56%)	6 (45%)	
ANCA type:				
PR3-ANCA	n (%)	8 (89%)	10 (91%)	0.360 [#]
MPO-ANCA	n (%)	0	1 (9%)	
ANCA negative	n (%)	1 (11%)	0	
Duration of SVV [years]	median [IQR]	2 [1-5]	3 [3-11]	0.296
CYC cumulative dose [g]	median [IQR]	9 [7.5-13.5]	13 [8.3-40]	0.470
CYC cumulative dose [mg/kg]	median [IQR]	105 [87-262]	157 [129-430]	0.447

RTX single dose [mg]	mean±SD	690±130	731±80	0.390
Baseline BVAS/WG score	median [IQR]	7 [7-9]	5 [4-12]	0.125
SVV course:				
- limited or severe flare	n (%)	5 (56%)	10 (91%)	0.069
- severe multiorgan flare	n (%)	4 (44%)	1 (9%)	
Dominant organ activity (presence of major symptoms):				
- eye	n (%)	1	0	-
- ENT	n (%)	1	3	
- pulmonary	n (%)	2	0	
- gastrointestinal	n (%)	0	1	
- renal	n (%)	4	0	
- nervous system	n (%)	1	2	
- other	n (%)	2	2	
Baseline ANCA titre [IU/mL]	median [IQR]	21 [2-102]	47 [10-124]	0.408
RTX efficacy:				
- complete remission	n (%)	9 (100%)	8 (73%)	0.236
- partial remission	n (%)	0	2 (18%)	
- inadequate response	n (%)	0	1 (9%)	

*P-values for Mann-Whitney's test, *p-value for t-test, #p-value for chi-square test.*